Screening forROS1gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target-Reference-Cited by-同舟云学术

Screening forROS1gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target

Published:2016-11-15 Issue:3 Volume:70 Page:402-411
ISSN:0309-0167
Container-title:Histopathology
language:en
Short-container-title:Histopathology

Author:

Selinger Christina I¹,Li Bob T²³⁴,Pavlakis Nick²⁴,Links Matthew⁵,Gill Anthony J⁴⁶,Lee Adrian²,Clarke Stephen²⁴,Tran Thang N¹,Lum Trina¹,Yip Po Y⁷⁸⁹¹⁰,Horvath Lisa⁴⁷¹¹,Yu Bing⁴¹²,Kohonen-Corish Maija R J⁷⁸¹³,O'Toole Sandra A¹⁴⁷,Cooper Wendy A¹⁴⁸

Affiliation:

1. Tissue Pathology and Diagnostic Oncology; Royal Prince Alfred Hospital; Camperdown NSW Australia

2. Department of Medical Oncology; Royal North Shore Hospital; St Leonards NSW Australia

3. Thoracic Oncology Service; Memorial Sloan Kettering Cancer Center; New York USA

4. Sydney Medical School; University of Sydney; Camperdown NSW Australia

5. Department of Medical Oncology; St George Hospital; Kogarah NSW Australia

6. Cancer Diagnosis and Pathology Group; Kolling Institute of Medical Research, Royal North Shore Hospital; St Leonards NSW Australia

7. The Kinghorn Cancer Centre; Garvan Institute of Medical Research; Darlinghurst NSW Australia

8. School of Medicine; University of Western Sydney; Sydney NSW Australia

9. Chris O'Brien Lifehouse; Camperdown NSW Australia

10. Macarthur Cancer Therapy Centre; Campbelltown Hospital; Camperdown NSW Australia

11. Medical Oncology; Royal Prince Alfred Hospital; Camperdown NSW Australia

12. Department of Medical Genomics; Royal Prince Alfred Hospital; Camperdown NSW Australia

13. St Vincent's Clinical School; University of New South Wales; Darlinghurst NSW Australia

Funder

CINSW

Sydney Breast Cancer Foundation

National Health and Medical Research Council

Tag family foundation

NIH/NCI Cancer Center Support

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/his.13076/fullpdf

Reference48 articles.

1. ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway;Ou;Expert Rev. Anticancer Ther.,2012

2. Cellular sequences related to three new onc genes of avian sarcoma virus (fps, yes, and ros) and their expression in normal and transformed cells;Shibuya;J. Virol.,1982

3. Genetic structure and transforming sequence of avian sarcoma virus UR2;Wang;J. Virol.,1982

4. Some biological properties of two new avian sarcoma viruses;Balduzzi;J. Virol.,1981

5. Matrix-independent activation of phosphatidylinositol 3-kinase, Stat3, and cyclin A-associated Cdk2 Is essential for anchorage-independent growth of v-Ros-transformed chicken embryo fibroblasts;Uttamsingh;J. Biol. Chem.,2003

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project;Lung Cancer;2024-08

2. Rediscovering immunohistochemistry in lung cancer;Critical Reviews in Oncology/Hematology;2024-08

3. The rapidly changing field of predictive biomarkers of non-small cell lung cancer;Pathology and Oncology Research;2024-06-17

4. Ros1 Fusions in Resected Stage I-Iii Adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape Project;2024

5. Concordance of Immunohistochemistry and Fluorescence In Situ Hybridization in the Detection of Anaplastic Lymphoma Kinase (ALK) and Ros Proto-oncogene 1 (ROS1) Gene Rearrangements in Non–Small Cell Lung Carcinoma: A 4.5-Year Experience Highlighting Challenges and Pitfalls;Archives of Pathology & Laboratory Medicine;2023-12-06